Skip to content

Impact of Symprove in Ehlers-Danlos Syndrome

A single-arm, decentralised, real-world evidence pilot study to assess the impact of Symprove in people with Ehlers- Danlos Syndrome (EDS)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN17931168
Enrollment
150
Registered
2026-02-26
Start date
2026-03-09
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ehlers-Danlos syndromes Genetic Diseases

Interventions

All participants will receive a 12-week course of Symprove (70 ml per day), a water-based solution that contains billions of live and active bacteria. The water-based formula makes sure that the bacte

Sponsors

Symprove Ltd
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Adults (18-75 years) resident in the UK who have either self-diagnosed or received a medical diagnosis of EDS (any subtype)

Exclusion criteria

Exclusion criteria: 1. Currently taking probiotics or prebiotics supplements (e.g. Bimuno) or yogurts containing probiotics (e.g. Yakult, Actimel) 2. Taken Symprove in the last 3 months 3. Taken antibiotics in the last 4 weeks 4. Diagnosed with gut conditions other than DGBIs, such as inflammatory bowel disease (e.g. Crohn’s disease or ulcerative colitis), coeliac disease, hepatitis, gallstones 5. Received gastrointestinal surgery, cancer treatment or been hospitalised in the last 6 months 6. Experiencing any psychological issues (such as depression, bipolar illness, psychosis) that are unstable and/or have recently changed medications for psychological issues 7. Diagnosed with any significant heart, lung or kidney issues 8. Currently pregnant or breastfeeding 9. Patients taking part in other interventional research where they are receiving treatment

Design outcomes

Primary

MeasureTime frame
Quality-of-life measured using EQ-5D-5L questionnaire at baseline, week 6, week 12

Secondary

MeasureTime frame
Gastrointestinal symptoms measured using the Gastrointestinal Symptom Rating Scale (GSRS) at baseline, weeks 6 and 12;Mental health measured using the Hospital Anxiety and Depression Scale (HADS) at baseline, weeks 6 and 12;Patient experience measured using study-specific questions (non-validated) at weeks 6 and 12;Adverse events/side effects measured using patient report on study surveys at weeks 6 and 12

Countries

England, United Kingdom

Contacts

Public ContactSusan Booth
research@ehlers-danlos.org+44 (0)800 246 1391

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 25, 2026